175140-00-8
基本信息
CP 376395 hydrochloride
CP376395
CP-376395
CP 376395
4-Pyridinamine, N-(1-ethylpropyl)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-
N-(1-Ethylpropyl)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-4-pyridinaminehydrochloride
物理化學(xué)性質(zhì)
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | HY-14130 | CP 376395 CP 376395 | 175140-00-8 | 5mg | 915元 |
2024/11/08 | HY-14130 | CP 376395 CP 376395 | 175140-00-8 | 10mM * 1mLin DMSO | 1006元 |
2024/11/08 | HY-14130 | CP 376395 CP 376395 | 175140-00-8 | 10mg | 1457元 |
常見問題列表
CRF1
CP 376395 fully antagonizes oCRF-stimulated adenylate cyclase activity in rat cerebral cortex and at human CRF1 receptors with an apparent K i value of 12 nM, indicating antagonist functional activity. It is highly selective for the human CRF1 receptor subtype; affinity for the CRF2 receptor is >10000 nM. It shows affinities greater than 1 μM against 40 neurotransmitter receptor and ion channels.
In the CNS, systemically administered CP 376395 blocks the effects of both exogenous and endogenous CRF. Pretreatment with CP 376395 reverses the excitation of locus coeruleus neurons induced by icv CRF (3 μg) with an ID 50 of completely blocked the enhanced startle response induced by icv CRF (1 μg) at 17.8 mg/kg, p.o. and partially blocked at 10 mg/kg, p.o. without significantly altering baseline startle. The attenuation of fear-potentiated startle is statistically significant at lower doses (0.32-3.2 mg/kg, p.o., with 62-83% blockade) and completely reversed by CP 376395 at 10 mg/kg, p.o.